Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00360529 · ClinicalTrials.gov registry record · Phase 3
24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder
A Phase 3 study, sponsored by Sprout Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 880
- Enrollment target
NCT00360529 is a Phase 3 study that has completed, run by Sprout Pharmaceuticals. The registered enrollment target is 880 participants.
The verdict
NCT00360529, a Phase 3 study, has completed, sponsored by Sprout Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 880 participants
- Enrollment target
Study Summary
This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.
Interventions
- DRUG flibanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 880 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00360529
The ClinicalTrials.gov registry entry for NCT00360529 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 880 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sprout Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which flibanserin is the first listed.
NCT00360529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00360529 about?
NCT00360529 is a clinical study titled "24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder". This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.
What is the current status of trial NCT00360529?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 880 participants. The study started on 2006-07. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00360529?
The interventions under investigation include: flibanserin (DRUG).
Who is sponsoring clinical trial NCT00360529?
This trial is sponsored by Sprout Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.